English
简体中文
繁體中文
客服热线:400-1616-289
登录
注册
会议论文
PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC)
Zhang, Jian; Meng, Yanchun; Wang, Biyun; Wu, Xinhong; Zheng, Hongmei; Cai, Li; Chen, Wenyan; Wang, Leiping; Cao, Jun; Tao, Zhonghua; Li, Ting; Ni Sujie; Yu, Zhengyan; Chen, XueSong; Peng, Qiang; Hu, Xin; Yao, Wenqing; Hu, Xichun
复旦大学; 南通大学; 哈尔滨医科大学; 1
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
2023-6-1
4
阅读
引用
收藏
分享
相关
加载中…
文献加载失败,请重试
重试